A Phase 4 interventional study of 5% inhaled nitrous oxide and 50% inhaled nitrous oxide in Endoscopy and Colonoscopy, sponsored by Stanford University. Withdrawn at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-27.
Sponsored by Stanford University · Phase 4, Interventional, and Treatment
Nitrous oxide (commonly known as 'laughing gas') is often used during dental and other outpatient procedures, because it is easy to administer, is short-acting and rapidly clears from the body following the procedure.
The investigators hypothesize that use of Nitrous oxide during GI endoscopy may enhance patient comfort during the procedure and speed-up post-procedure recovery, while minimizing the fatigue and mental fogginess some patients report the day after receiving standard sedative and narcotic drugs used routinely for the procedure.
The investigators are interested in determining if adding Nitrous Oxide to commonly used sedation drugs will decrease fatigue, mental fogginess, and nausea/vomiting, as well as determine when the patient felt fully recovered from the effects of all sedatives given for the procedure.
Stanford University is the lead sponsor of 2,117 studies on the registry; 425 are open to participants now.
Of its 259 completed or terminated interventional studies of FDA-regulated products, 197 (76%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Patients will received 5% nitrous oxide by face mask in addition to standard intravenous sedatives given at the discretion of the care provider.
Drug: 5% inhaled nitrous oxide
Patients will received 50% nitrous oxide by face mask in addition to standard intravenous sedatives given at the discretion of the care provider.
Drug: 50% inhaled nitrous oxide
5% Nitrous oxide will be administered by face or nasal mask to be inhaled by the patient
50% Nitrous oxide will be administered by face or nasal mask to be inhaled by the patient
Intravenous sedative drug
Tabulate the types and dosages of intravenous sedative drugs given
Time frame: Duration of the procedure (1-2 hours)
Recovery time
Time spent in procedure room to recover
Time frame: Duration of the procedure (1-3hours)
Patient comfort
Patient comfort rating intra-procedure using standardized scale
Time frame: Duration of the procedure (1-3hours)
Fatigue
The number of patients who experienced fatigue
Time frame: 24-36 hours
Fatigue
The duration of fatigue experienced, if any
Time frame: 24-36 hours
Nausea/vomiting
Number of patients who experienced nausea/vomiting
Time frame: 24-36 hours
Nausea/vomiting
Duration of nausea/vomiting
Time frame: 24-36 hours
Mental Fogginess post-procedure/sedation
Duration of mental fogginess following the procedure/sedation
Time frame: 24-36 hours
Mental Fogginess post-procedure/sedation
Number of patients who experienced mental fogginess post-procedure/sedation
Time frame: 24-36 hours
Return to baseline function
Number of hours post-procedure/sedation for patient to return to baseline function
Time frame: 24-36 hours
Plan to share: No
No publications or documents are linked to this record.
This study is withdrawn, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Stanford University